Hanyang University Researchers Develop AI-designed Shape-Shifting Microneedles for Diabetic Wound Healing
On Jun. 26, 2026, Chronic diabetic wounds heal slowly and are highly vulnerable to infection. Researchers report developing…
-
-
Self-propelled actin filaments: Novel structures driving spontaneous cell morphogenesis
On Jun. 25, 2026, researchers from the Nara Institute of Science and Technology report that every time a…
-
Dementia Will Cost the U.S. $818 Billion in 2026, USC-Led Study Finds
On Jun. 24, 2026, A University of Southern California (USC)-led study finds Alzheimer’s disease and related dementias will…
-
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
On Jun. 24, 2026, Antares Therapeutics announce it has entered a collaboration with Novartis that could be worth…
-
Nanoparticles sneak antibodies into cells to inhibit cancer, inflammation
On Jun. 23. 2026, scientists at Cornell University announce discovering a delivery system that uses lipid nanoparticles to…
-
Biotechnology | CDC | Diagnostics | Infectious Disease | NIH | Therapeutics | Vaccine | WHO
US provides Ebola treatment for outbreak in Congo, bringing trials closer
On Jun. 23, 2026, the U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for…
-
Manning Family Children’s makes history as Louisiana’s first Sickle Cell Disease gene therapy marking his functional cure
On Jun. 22, 2026, Louisiana’s first Sickle Cell Disease gene therapy patient is now set to pursue his…
-
USC Stem Cell-led team creates a renewable cell source for cancer immunotherapy and beyond
On Jun. 19, 2026, University of Southern California (USC) scientists report in a paper published in Cell, a…
-
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera for $1 Billion
On Jun. 17, 2026, Biogen and RayThera, a private biotechnology company focused on discovering and developing small molecule…
-
FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
On Jun. 16, 2026, the U.S. Food and Drug Administration (FDA) approved another over-the-counter (OTC) intranasal naloxone product,…
-
USDA Invests in Projects to Strengthen New World Screwworm Preparedness and Response
On Jun. 16, 2026, the U.S. Department of Agriculture (USDA) is announcing funding for 40 breakthrough projects to…
-
Biotechnology | Disease | NIH | Therapeutics
University of Oklahoma Receives $11.5 Million NIH Award to Establish Statewide Immunoengineering Research Center
On Jun. 11, 2026, the University of Oklahoma (OU) announced it had received an $11.5 million award from…
-
FDA Issues EUA for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
On Jun. 11, 2026, The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for generic…
-
USDA Responds to New World Screwworm; New Case Confirmed in La Salle County, Texas
On Jun. 9, 2026, The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS), alongside…
-
First-in-the-world gene therapy delivers missing gene directly to infant’s brain, marking historic milestone in precision medicine
On Jun. 8, 2026, an eight-month-old infant with a severe genetic epilepsy has become the first patient in…
-
Artificial Intelligence | Biotechnology | Clinical Research | Genomics | Pharmaceutical | Therapeutics
Google DeepMind, Google.org and Sanger Institute to launch new AI consortium for genomics
On Jun. 8, 2026, the Wellcome Sanger Institute, Google.org, and Google DeepMind announced they are partnering up to…
-
Incyte to Acquire Vega Therapeutics, Subsidiary of Star Therapeutics, for $1.25 billion, Expanding its Hematology Portfolio into Bleeding Disorders
On Jun. 8, 2026, Incyte announced it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned…
-
Roche announces global collaboration with Nurix Therapeutics worth up to $2.3 billion
On Jun. 7, 2026, Roche announced that it has entered into an exclusive licensing and collaboration agreement with…
-
Bioprinting Cartilage, Producing Stem Cells Fill ISS Research Schedule
On Jun. 4, 2026, 3D bioprinting and stem cell research were the main research topics aboard the International…
-
Lilly gains license for Ascidian’s gene-editing tech to develop kidney disease drugs worth up to $1.9 billion
On Jun. 3, 2026, Ascidian Therapeutics said it has signed a licensing deal for its gene-editing technology with…
-
Flesh-eating screwworm may have been detected in South Texas, USDA says
On Jun. 3, 2026, an infestation of the flesh-eating screwworm parasite may have been detected in South Texas,…
-
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics Worth Up to $2 Billion
On Jun. 3, 2026, Alnylam Pharmaceuticals, the leading RNAi therapeutics company, and Inceptive Nucleics, which builds foundation models…
-
Microrobots repair spinal cord
On Jun. 2, 2026, a research team from ETH Zurich and the University of Zurich (UZH) announced it…
-
Pfizer and China’s Innovent Biologics Enter Global Strategic Collaboration worth $9.85 billion to Accelerate Development of Oncology Medicines
On May 28, 2026, Pfizer and Innovent Biologics announced the companies have entered into a strategic global licensing…
-
Abbott secures CE Mark for world’s first dual glucose-ketone sensing technology for people with diabetes
On May 27, 2026, Abbott announced it has secured CE Mark for the world’s first dual glucose‑ketone sensing…
-
Lilly announces three acquisitions to build infectious disease portfolio for $3.8 Billion in Cash
On May 26, 2026, Eli Lilly announced agreements to acquire three companies, Curevo, LimmaTech Biologics, and Vaccine Company,…
-
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus
On May 22, 2026, Gilead Sciences announced announced that the U.S. Food and Drug Administration (FDA) has granted…
-
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer
On May 22, 2026, Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of…
-
Engage Bio Acquired by Lilly for $202 million in cash to Accelerate Development of Non-Viral Genetic Medicines
On May 20, 2026, Engage Biologics, a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it…
-
Ebola Epidemic caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a public health emergency of international concern
On May 17, 2026, the Director-General of the World Health Organization (WHO) announced that the Ebola disease caused…
